Wednesday September 16, 2026 5:27 PM ET

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Monday August 24, 2026 4:05 PM ET

Longeveron Announces 1-for-10 Reverse Stock Split

Wednesday August 19, 2026 4:05 PM ET

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wednesday August 12, 2026 4:05 PM ET

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Tuesday August 11, 2026 9:05 AM ET

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Monday August 3, 2026 4:05 PM ET

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Thursday July 23, 2026 9:15 AM ET

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Monday July 13, 2026 7:05 AM ET

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

Monday July 6, 2026 4:05 PM ET

Longeveron® Appoints Marie Washburn as Chief Financial Officer

Thursday June 18, 2026 9:20 AM ET

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)

Tuesday June 9, 2026 9:20 AM ET

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Thursday June 4, 2026 9:15 AM ET

Longeveron to Present at BIO International Convention 2026

Wednesday May 20, 2026 4:05 PM ET

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

Wednesday May 13, 2026 4:05 PM ET

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

Monday May 11, 2026 9:10 AM ET

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Friday May 8, 2026 4:05 PM ET

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Tuesday May 5, 2026 4:15 PM ET

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Wednesday April 8, 2026 9:15 AM ET

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)